Variables | Total , N = 272 | Cases (n = 78) | Controls (n = 194) | Chi2(df) | p-value | ||
---|---|---|---|---|---|---|---|
N (%) | N (%) | Â | Â | ||||
Duration on ART | < 5 years | 18 (6.6) | 13 (16.7) | 5(2.6) | 20.11 (2) | < 0.001 | |
5–10 years | 93 (34.2) | 29 (37.2) | 64 (32.9) |  |  | ||
> 10 years | 161 (59.2) | 36 (46.2) | 125 (64.4) |  |  | ||
Daily ART dose | One | 174 (64.0) | 37 (47.4) | 137 (70.6) | 12.97 (1) | < 0.001 | |
Two | 98 (36.0) | 41(52.6) | 57 (29.4) | Â | Â | ||
Base line CD4 Count (cells/mm3) | < 200 | 14 (5.1) | 8 (10.3) | 6 (3.1) | 8.38 (3) | 0.039 | |
200–499 | 65 (23.9) | 18 (23.1) | 47 (24.2) |  |  | ||
>=500 | 180 (66.2) | 46 (59.0) | 134 (69.1) | Â | Â | ||
Not recorded | 13 (4.8) | 6 (7.7) | 7(3.6) | Â | Â | ||
ART regimen backbone | AZT + 3TC | 68 (25.0) | 34 (43.6) | 34 (17.5) | 33.78 (2) | < 0.001 | |
 | TDF + 3TC | 161 (59.2) | 25 (32.1) | 136 (70.1) |  |  | |
 | ABC + 3TC | 43 (15.8) | 19 (24.4) | 24 (12.4) |  |  | |
Variables | Total , N = 272 | Cases (n = 78) | Controls (n = 194) | Chi2(df) | p-value | ||
N (%) | N (%) | Â | Â | ||||
Viral load change from baseline values (copies/mL) | Remained ND | 91 (33.5) | 9 (11.5) | 82 (42.3) | 28.23 (2) | < 0.001 | |
No change or become < 1000 | 58 (21.3) | 16 (20.5) | 42 (21.7) |  |  | ||
≥ 1000 or increased from ND | 123 (45.2) | 53 (68.0) | 70 (36.1) |  |  | ||
WHOs clinical stage on admission | Stage-1 | 217 (79.8) | 64(82.1) | 153(78.9) | 3.32 (2) | 0.190 | |
Stage-2 | 38 (14.0) | 7(8.9) | 31(15.9) | Â | Â | ||
Stage-3 | 17 (6.2) | 7(8.9) | 10(5.2) | Â | Â | ||
Experienced side effect | Yes | 30 | 9 (11.5) | 21 (10.8) | 0.029 (1) | 0.865 | |
 | No | 242 | 69 (88.5) | 173 (89.2) |  |  |